Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
March 17, 2014

Top R&D Spenders of 2013

These companies invest the most money in the search for new drugs.

Top R&D Spenders of 2013

Meet the big spenders, ranked by total R&D expenses. [© Melpomene - Fotolia.com]

  • For all the talk about biopharmas cutting back on research and development, more companies (12) actually increased their R&D spending in 2013 than decreased it (eight), if the latest GEN List is any indication.

    Reasons for the fluctuations vary. Inevitably, companies that ramped up their R&D spending the most cited the need to support later-stage clinical programs, while biopharmas that reduced R&D spending often—but not always—did so as part of companywide restructurings designed to cut costs and enhance efficiency.

    Most but not all heritage “big pharma” companies reduced R&D, while biotechs continued to increase their R&D spending—yet remain below the levels of the pharma giants.

    However, two U.K.-based biopharmas (GlaxoSmithKline and AstraZeneca) restated their 2012 R&D expenses, by lowering them from figures originally announced for that year (and in one case, subsequently published last year in GEN’s List of Top 20 R&D Spenders in 2012). The companies cited the revision of International Accounting Standard (IAS) 19 that took effect in 2013. The change eliminated the option to defer the recognition of actuarial gains and losses from defined benefit post-employment plans.

    For companies whose spending is converted into dollars from other currencies, some of the 2012 figures reported this year differ from those in the original list, reflecting currency fluctuations since then. Following is GEN’s List of Top 20 R&D Spenders for 2013, ranked by total R&D expenses as reported in annual filings or press releases. Each company is listed by name, 2013 spending, 2012 spending, and the percentage change from 2012.

  • #20. Merck KGaA

    2013 R&D spending: $1.638 billion (€1.183 billion)1
    2012 R&D spending: $1.644 billion (€1.187 billion)1
    % Change: -0.3%

  • #19. Astellas Pharma

    2013 R&D spending: $1.771 billion (¥182.000 billion)
    2012 R&D spending: $1.846 billion (¥189.800 billion)
    % Change: -4.1%

  • #18. Daiichi Sankyo

    2013 R&D spending: $1.777 billion (¥183.047 billion)
    2012 R&D spending: $1.796 billion (¥185.052 billion)
    % Change: -1.1%

  • #17. Gilead Sciences

    2013 R&D spending: $2.120 billion
    2012 R&D spending: $1.760 billion
    % Change: 20.5%

  • #16. Novo Nordisk

    2013 R&D spending: $2.178 billion (DKK 11.733 billion)
    2012 R&D spending: $2.023 billion (DKK 10.897 billion)
    % Change: 7.7% 

  • #15. Celgene

    2013 R&D spending: $2.226 billion
    2012 R&D spending: $1.724 billion
    % Change: 29.1%

  • #14. Bayer

    2013: R&D spending: $2.291 billion (€1.654 billion)2
    2012: R&D spending: $2.162 billion (€1.561 billion)2
    % Change: 6.0%

  • #13. AbbVie3

    2013 R&D spending: $2.855 billion3
    2012 R&D spending: $2.778 billion3
    % Change: 2.8%

  • #12. Takeda Pharmaceutical

    2013 R&D spending: $3.148 billion (¥324.292 billion)
    2012 R&D spending: $2.737 billion (¥281.885 billion)
    % Change: 15.0%

  • #11. Bristol-Myers Squibb

    2013 R&D spending: $3.731 billion
    2012 R&D spending: $3.904 billion
    % Change: -4.4%

Related content